{"prompt": "['Product: MK-3475', '101', 'Protocol/Amendment No.: 604-09', '8.1 Statistical Analysis Plan Summary', 'Key elements of the Statistical Analysis Plan (SAP) are summarized below. The', 'comprehensive plan is provided in Section 8.2 through Section 8.12.', 'Analysis Strategy for Key Efficacy Endpoints', 'Study Design Overview', 'This is a Phase 3, randomized, multi-site, double-blind study of 1L', 'pembrolizumab+El versus saline placebo+EP in ES-SCLC (KEYNOTE-', '604)', 'Treatment Assignment', 'Approximately 430 subjects were planned to be randomized in a 1:1 ratio to', 'receive pembrolizumab+EP or saline placebo+EP. The stratification factors', 'used for this study are a) cisplatin vs carboplatin, b) ECOG status (0 VS 1),', 'and, c) LDH at baseline (< vs ULN). This is a double-blind study.', 'By the time of the current amendment, 453 subjects were randomized for', 'the study.', 'Analysis Populations', 'Efficacy: Intention-to-Treat (ITT)', 'Safety: All Subjects as Treated (ASaT)', 'Primary Endpoints', '1) PFS as assessed by BICR RECIST 1.1 modified to follow a maximum', 'of 10 target lesions and a maximum of 5 target lesions per organ', '2) os', 'Secondary Endpoints', '3) ORR as assessed by BICR per RECIST 1.1 modified to follow a', 'maximum of 10 target lesions and a maximum of 5 target lesions per', 'organ', '4) DOR as assessed by BICR per RECIST 1.1 modified to follow a', 'maximum of 10 target lesions and a maximum of 5 target lesions per', 'organ', '5) AEs', 'Statistical Methods for', 'The primary hypotheses will be evaluated by comparing 1L', 'Key Efficacy Analyses', 'pembrolizumab+El to 1L saline placebo+EP based on PFS as assessed by', 'BICR RECIST 1.1 modified to follow a maximum of 10 target lesions and', 'a maximum of 5 target lesions per organ and os in subjects with ES-SCLC', 'using a stratified log-rank test. Hazard ratios (HRs) will be estimated using', 'a stratified Cox regression model. Event rates over time will be estimated', 'within each treatment group using the Kaplan-Meier method.', 'Statistical Methods for', 'The analysis of safety results will follow a tiered approach. There are no', 'Key Safety Analyses', 'Tier 1 safety parameters in this trial. All safety parameters are considered', 'either Tier 2 or Tier 3. Tier 2 parameters will be assessed via point', 'estimates with 95% CIs provided for between-group comparisons; only', 'point estimates by treatment group are provided for Tier 3 safety', 'parameters. The between-treatment difference will be analyzed using the', 'Miettinen and Nurminen method.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '102', 'Protocol/Amendment No.: 604-09', 'Interim and Final', 'Two interim analyses are planned in this study. Results will be reviewed', 'Analyses', 'by the external DMC. Details are provided in Section 8.7 - Interim', 'Analyses.', 'Interim analysis 1', 'Timing: To be performed at approximately 18 months from', 'study start, where study start is the date on which the first', 'subject was randomized. ORR p-value from the first interim', 'analysis (IA1) may be evaluated for statistical significance if PFS', 'and os null hypotheses are rejected at IA1 or at a later analysis', 'time.', 'Purpose: Interim PFS and os analyses to demonstrate superiority', 'of pembrolizumab+EP over saline placebo+EP.', 'Interim analysis 2', 'Timing: To be performed at approximately 22 months from study', 'start. Purpose: Final PFS analysis and interim os analysis to', 'demonstrate superiority of pembrolizumab+EP over saline', 'placebo+EP', 'Final analysis', 'Timing: To be performed after a minimum of 294 deaths are', 'observed or approximately 31 months after first subject enrolled,', 'whichever occurs later.', 'Purpose: Final analysis of os to demonstrate superiority of', 'pembrolizumab+EP over saline placebo+EP', 'Multiplicity', 'The family-wise type I error rate for this study is strongly controlled at', '2.5% (one-sided) for the hypothesis testing of PFS, OS, and ORR. The', 'multiplicity strategy will follow the graphical approach of Maurer and', 'Bretz [114] as described in Section 8.8, with 0.6% and 1.9% alpha initially', 'allocated to the PFS and os hypotheses, respectively. Group sequential', 'methods will be used to allocate alpha between the interim and final', 'analyses for PFS and os endpoints. Further details of the interim analysis', 'strategy can be found in Section 8.7 and Section 8.8.', 'Sample Size and Power', 'The planned sample size is approximately 430 subjects. The actual sample', 'size is 453 subjects. For PFS, based on 387 events, the study has 95.6%', 'power to detect a HR of 0.65 (pembrolizumab+E vs saline placebo+EP) at', '=0.6% (one-sided). For OS, based on a minimum of 294 events, the study', 'has at least 94.4% power to detect a HR of 0.65 (pembrolizumab+EP VS', 'saline placebo+EP) at =1.9% (one-sided).', '8.2', 'Responsibility for Analyses/In-house Blinding', 'The statistical analysis of the data obtained from this study will be the responsibility of the', 'Clinical Biostatistics department of the Sponsor.', 'The Sponsor will generate the randomized allocation schedule for study treatment', 'assignment for this protocol and the randomization will be implemented in IVRS/IWRS.', 'Planned interim analyses are described in Section 8.7. Participant-level unblinding will be', 'restricted to an external unblinded statistician and scientific programmer performing the', 'interim analysis, who will have no other responsibilities associated with the study.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}